India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Witfire Elite View · Pharma Market Case Study · Updated 12 June 2026 The cheapest semaglutide in the world is made in India — and the price collapse it triggered is now reaching the United States. Roughly three months after Novo Nordisk’s core Indian patent expired and more than 40 local drugmakers flooded the market with generic Ozempic and Wegovy…
Trending News
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
The stock market is now looking at the US-Israel-Iran conflict through a sharper…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain…
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy…
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion | Witfire Elite View…
Editorial picks
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Witfire Elite View · Pharma Market Case Study · Updated 12 June 2026 The cheapest semaglutide in the world is made in India — and the price collapse it triggered is now reaching the United States. Roughly three months after Novo Nordisk’s core Indian patent expired and more than 40…
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Categories
Investments
business news
Entrepreneurship
Startups
2026
INSIGHTS FOR THE NEW PHARMA LEADERS
Witfire Elite brings focused perspectives on pharma growth, innovation, manufacturing, startups, and executive strategy.
Around The World
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Breaking Case Study FDA & Regulatory Intelligence Witfire Elite View FTX-6058 and Pociredir FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug FTX-6058 and Pociredir showed strong early sickle cell data, but FDA’s PRC2…
Pharma News
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Witfire Elite View · Pharma Market Case Study · Updated 12 June 2026 The cheapest semaglutide in the…
Eli Lilly Retatrutide Phase 3 Results at ADA 2026
Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View…
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug | Witfire Elite View Witfire…